The following clinically significant adverse reactions are discussed in more detail in other sections of the labeling:<br>Most common adverse reaction (≥5% and twice the rate of placebo): - Tardive dyskinesia: somnolence. ( 6.1 ) - Chorea associated with Huntington’s disease: somnolence/lethargy/sedation, urticaria, rash, insomnia. ( 6.1 )<br>To report SUSPECTED ADVERSE REACTIONS, contact Neurocrine Biosciences, Inc. at 877-641-3461 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.<br>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.<br>The safety of INGREZZA SPRINKLE has been established from adequate and well-controlled studies of INGREZZA [see Clinical Studies ( 14 )] . Below is a display of the adverse reactions of INGREZZA in these adequate and well-controlled studies.<br>Tardive Dyskinesia<br>Variable and Fixed Dose Placebo-Controlled Trial Experience<br>The safety of INGREZZA was evaluated in 3 placebo-controlled studies, each 6 weeks in duration (fixed dose, dose escalation, dose reduction), including 445 patients. Patients were 26 to 84 years of age with moderate to severe tardive dyskinesia and had concurrent diagnoses of mood disorder (27%) or schizophrenia/ schizoaffective disorder (72%). The mean age was 56 years. Patients were 57% Caucasian, 39% African-American, and 4% other. With respect to ethnicity, 28% were Hispanic or Latino. All subjects continued previous stable regimens of antipsychotics; 85% and 27% of subjects, respectively, were taking atypical and typical antipsychotic medications at study entry.<br>Adverse Reactions Leading to Discontinuation of Treatment<br>A total of 3% of INGREZZA-treated patients and 2% of placebo-treated patients discontinued because of adverse reactions.<br>Common Adverse Reactions<br>Adverse reactions that occurred in the 3 placebo-controlled studies at an incidence of ≥2% and greater than placebo are presented in Table 1 .<br>1 Within each adverse reaction category, the observed adverse reactions are listed in order of decreasing frequency.<br>Other Adverse Reactions Observed During the Premarketing Evaluation of INGREZZA<br>Other adverse reactions of ≥1% incidence and greater than placebo are shown below. The following list does not include adverse reactions: 1) already listed in previous tables or elsewhere in the labeling, 2) for which a drug cause was remote, 3) which were so general as to be uninformative, 4) which were not considered to have clinically significant implications, or 5) which occurred at a rate equal to or less than placebo.<br>Endocrine Disorders: blood glucose increased<br>General Disorders: weight increased<br>Infectious Disorders: respiratory infections<br>Neurologic Disorders: drooling, dyskinesia, extrapyramidal symptoms (non-akathisia)<br>Psychiatric Disorders: anxiety, insomnia<br>During the tardive dyskinesia controlled trials, there was a dose-related increase in prolactin. Additionally, in these trials there was a dose-related increase in alkaline phosphatase and bilirubin, suggesting a potential risk for cholestasis.<br>Chorea Associated with Huntington ’s Disease<br>The safety of INGREZZA was evaluated in a 14-week placebo-controlled study including 127 patients with chorea associated with Huntington’s disease. Patients were 25 to 75 years of age. The mean age was 54 years. Patients were 96% Caucasian, 1% African-American, 1% Asian, and 2% Other. With respect to ethnicity, 6% were Hispanic or Latino.<br>Adverse Reactions Leading to Discontinuation of Treatment<br>A total of 8% of INGREZZA-treated patients and 6% of placebo-treated patients discontinued because of adverse reactions.<br>Common Adverse Reactions<br>Adverse reactions that occurred in the placebo-controlled study at an incidence of ≥4% and greater than placebo are presented in Table 2 .<br>The following adverse reactions have been identified during post-approval use of INGREZZA that are not included in other sections of labeling. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.<br>Immune System Disorders: hypersensitivity reactions (including allergic dermatitis and pruritis)<br>Adverse Reaction 1 INGREZZA (n=262) % Placebo (n=183) % <br>General Disorders <br>Somnolence (somnolence, fatigue, sedation) 10.9 4.2 <br>Nervous System Disorders <br>Anticholinergic effects 5.4 4.9 <br>(dry mouth, constipation, disturbance in attention, vision   <br>blurred, urinary retention)   <br>Balance disorders/fall (fall, gait disturbance, dizziness, balance disorder) 4.1 2.2 <br>Headache 3.4 2.7 <br>Akathisia (akathisia, restlessness) 2.7 0.5 <br>Gastrointestinal Disorders <br>Vomiting 2.6 0.6 <br>Nausea 2.3 2.1 <br>Musculoskeletal Disorders <br>Arthralgia 2.3 0.5 <br>Adverse Reaction INGREZZA (n=64) % Placebo (n=63) % <br>Nervous System Disorders <br>Somnolence, lethargy, sedation 18.8 3.2 <br>Akathisia 6.3 4.8 <br>General Disorders and Administration Site Conditions <br>Fatigue 14.1 9.5 <br>Skin and Subcutaneous Tissue Disorders <br>Urticaria 9.4 0 <br>Rash 7.8 0 <br>Gastrointestinal Disorders <br>Diarrhea 4.7 1.6 <br>Nausea 4.7 0 <br>Psychiatric Disorders <br>Insomnia, middle insomnia 6.3 1.6 <br>Depression, depressed mood 4.7 1.6 <br>Musculoskeletal D isorders <br>Back pain 4.7 0 <br><content styleCode="bold">6 </content><br>                      <br>    <content styleCode="bold">ADVERSE REACTIONS</content><br>                   <br>  The following clinically significant adverse reactions are discussed in more detail in other sections of the labeling: Depression and Suicidal Ideation and Behavior in Patients with Huntington’s Disease [see Boxed Warning and Warnings and Precautions ( 5.1 )] Hypersensitivity Reactions [see Contraindications ( 4 ) and Warnings and Precautions ( 5.2 ) ] Somnolence and Sedation [see Warnings and Precautions ( 5.3 )] QT Prolongation [see Warnings and Precautions ( 5.4 )] Neuroleptic Malignant Syndrome (NMS) [see Warnings and Precautions ( 5.5 )] Parkinsonism [see Warnings and Precautions ( 5.6 )] Most common adverse reaction (≥5% and twice the rate of placebo): - Tardive dyskinesia: somnolence. ( 6.1 ) - Chorea associated with Huntington’s disease: somnolence/lethargy/sedation, urticaria, rash, insomnia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Neurocrine Biosciences, Inc. at 877-641-3461 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. <br>                                <br>        <content styleCode="bold">6.1 </content><br>                                <br>        <content styleCode="bold">Clinical Trials Experience</content><br>                             <br>      Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of INGREZZA SPRINKLE has been established from adequate and well-controlled studies of INGREZZA [see Clinical Studies ( 14 )] . Below is a display of the adverse reactions of INGREZZA in these adequate and well-controlled studies. Tardive Dyskinesia Variable and Fixed Dose Placebo-Controlled Trial Experience The safety of INGREZZA was evaluated in 3 placebo-controlled studies, each 6 weeks in duration (fixed dose, dose escalation, dose reduction), including 445 patients. Patients were 26 to 84 years of age with moderate to severe tardive dyskinesia and had concurrent diagnoses of mood disorder (27%) or schizophrenia/ schizoaffective disorder (72%). The mean age was 56 years. Patients were 57% Caucasian, 39% African-American, and 4% other. With respect to ethnicity, 28% were Hispanic or Latino. All subjects continued previous stable regimens of antipsychotics; 85% and 27% of subjects, respectively, were taking atypical and typical antipsychotic medications at study entry. Adverse Reactions Leading to Discontinuation of Treatment A total of 3% of INGREZZA-treated patients and 2% of placebo-treated patients discontinued because of adverse reactions. Common Adverse Reactions Adverse reactions that occurred in the 3 placebo-controlled studies at an incidence of ≥2% and greater than placebo are presented in Table 1 . Table 1: Adverse Reactions in 3 Placebo-Controlled Studies of 6-week Treatment Duration Reported at ≥2% and >Placebo – Tardive Dyskinesia Adverse Reaction 1 INGREZZA (n=262) % Placebo (n=183) % General Disorders Somnolence (somnolence, fatigue, sedation) 10.9 4.2 Nervous System Disorders Anticholinergic effects 5.4 4.9 (dry mouth, constipation, disturbance in attention, vision blurred, urinary retention) Balance disorders/fall (fall, gait disturbance, dizziness, balance disorder) 4.1 2.2 Headache 3.4 2.7 Akathisia (akathisia, restlessness) 2.7 0.5 Gastrointestinal Disorders Vomiting 2.6 0.6 Nausea 2.3 2.1 Musculoskeletal Disorders Arthralgia 2.3 0.5 1 Within each adverse reaction category, the observed adverse reactions are listed in order of decreasing frequency. Other Adverse Reactions Observed During the Premarketing Evaluation of INGREZZA Other adverse reactions of ≥1% incidence and greater than placebo are shown below. The following list does not include adverse reactions: 1) already listed in previous tables or elsewhere in the labeling, 2) for which a drug cause was remote, 3) which were so general as to be uninformative, 4) which were not considered to have clinically significant implications, or 5) which occurred at a rate equal to or less than placebo. Endocrine Disorders: blood glucose increased General Disorders: weight increased Infectious Disorders: respiratory infections Neurologic Disorders: drooling, dyskinesia, extrapyramidal symptoms (non-akathisia) Psychiatric Disorders: anxiety, insomnia During the tardive dyskinesia controlled trials, there was a dose-related increase in prolactin. Additionally, in these trials there was a dose-related increase in alkaline phosphatase and bilirubin, suggesting a potential risk for cholestasis. Chorea Associated with Huntington ’s Disease The safety of INGREZZA was evaluated in a 14-week placebo-controlled study including 127 patients with chorea associated with Huntington’s disease. Patients were 25 to 75 years of age. The mean age was 54 years. Patients were 96% Caucasian, 1% African-American, 1% Asian, and 2% Other. With respect to ethnicity, 6% were Hispanic or Latino. Adverse Reactions Leading to Discontinuation of Treatment A total of 8% of INGREZZA-treated patients and 6% of placebo-treated patients discontinued because of adverse reactions. Common Adverse Reactions Adverse reactions that occurred in the placebo-controlled study at an incidence of ≥4% and greater than placebo are presented in Table 2 . Table 2: Adverse Reactions in the Placebo-Controlled Study of 12-week Treatment Duration Reported at ≥4% and >Placebo – Chorea Associated with Huntington’s Disease Adverse Reaction INGREZZA (n=64) % Placebo (n=63) % Nervous System Disorders Somnolence, lethargy, sedation 18.8 3.2 Akathisia 6.3 4.8 General Disorders and Administration Site Conditions Fatigue 14.1 9.5 Skin and Subcutaneous Tissue Disorders Urticaria 9.4 0 Rash 7.8 0 Gastrointestinal Disorders Diarrhea 4.7 1.6 Nausea 4.7 0 Psychiatric Disorders Insomnia, middle insomnia 6.3 1.6 Depression, depressed mood 4.7 1.6 Musculoskeletal D isorders Back pain 4.7 0 <br>                                <br>        <content styleCode="bold">6.2 </content><br>                                <br>        <content styleCode="bold">Postmarketing Experience</content><br>                             <br>      The following adverse reactions have been identified during post-approval use of INGREZZA that are not included in other sections of labeling. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Immune System Disorders: hypersensitivity reactions (including allergic dermatitis and pruritis)